Tuberculosis during JAK inhibitor or TNF-α inhibitors therapy: a disproportionality analysis from WHO pharmacovigilance database.
Small-molecule oral Janus kinase (JAK) inhibitors are increasingly used for treatment of digestive and rheumatic inflammatory diseases or haematological disorders. Based on limited data, the risk of tuberculosis (TB) has been reported but considered lower compared with that observed with TNF-α inhibitors a finding we p...